Authorities issue warning after spotting dolphins in unexpected location: 'Vulnerable and unpredictable'
According to the BBC, the dolphin was first seen gliding through the waters of Lyme Regis Harbour in Dorset. While it has become a local spectacle, experts say the excitement could put the animal at serious risk.
As a result, officials have launched Operation Seabird, a campaign aimed at protecting marine mammals from disturbance.
The Marine Management Organisation, Dorset Wildlife Trust, and Dorset Police are working together to remind the public that dolphins, whales, and porpoises are protected by law.
"The arrival of a dolphin in a small coastal community like Lyme Regis can be a source of wonder and pride," said Jess Churchill-Bissett, head of marine conservation, per the BBC. "But it's vital to remember dolphins are vulnerable and unpredictable wild animals, protected by law."
Under U.K. law, intentionally approaching or disturbing a dolphin could result in up to six months in prison or an unlimited fine. Even well-meaning actions — like trying to swim with, touch, or feed the animal — can be harmful.
"We all have a responsibility to respect their space, keep a safe distance, and understand how our actions can unintentionally cause harm or even constitute a criminal offence," Churchill-Bissett added.
While the dolphin may appear playful or curious, experts warn that crowding, noise, or reckless boating can cause extreme stress to the animal. Such encounters are becoming more common as warming waters and human development drive marine life closer to shore.
"By giving these animals space, observing them from a distance and acting responsibly, we help ensure their health and survival, so they remain a part of our coast now and for generations to come," Churchill-Bissett told the BBC.
This type of human-wildlife interaction also reflects a deeper issue: as ocean ecosystems face pressure from overfishing, habitat degradation, and increasing global temperatures, animals are often pushed out of their natural environments in search of food or safety, bringing them closer to human activity.
Do you think America is in a housing crisis?
Definitely
Not sure
No way
Only in some cities
Click your choice to see results and speak your mind.
To protect the dolphin and educate the public, officials have issued clear guidance: boaters should slow to under six knots, keep at least 100 meters (about 328 feet) away, and never try to interact with the animal.
If the dolphin approaches on its own, people are urged to maintain a steady course and allow the animal to leave on its own terms.
Globally, conservation groups are working to preserve marine habitats, regulate harmful fishing practices, and limit pollution that disrupts ocean ecosystems. These efforts are especially urgent as warmer waters and human development continue to shift the natural patterns of marine species.
Respecting wildlife boundaries isn't just about protecting animals, it's about preserving the health of our oceans and coastlines for the communities that depend on them. Every safe, respectful encounter is a small step toward helping marine life thrive.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
24 minutes ago
- Medscape
MHRA Approves First Targeted Drug for SOD1-ALS
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved tofersen (Qalsody, Biogen) for treating amyotrophic lateral sclerosis (ALS) in adults with mutations in the superoxide dismutase 1 (SOD1) gene, also known as SOD1-ALS. The approval makes tofersen the first targeted therapy in the UK against this rare form of motor neurone disease (MND) with a genetic basis. A Rare but Aggressive Condition SOD1-ALS causes the body to produce a misfolded, toxic version of the SOD1 protein. This triggers motor neuron degeneration in the brain and spinal cord. Patients experience progressive muscle weakness, atrophy, respiratory decline, and eventual paralysis and death. SOD1 mutations are responsible for approximately 2% of all ALS cases globally. Over 200 distinct mutations in SOD1 have been identified, each contributing to a wide range of disease progression rates. This variability highlights the importance of developing targeted therapies for SOD1-ALS. How Tofersen Works Tofersen is an antisense oligonucleotide that binds to SOD1 mRNA, promoting its degradation through an RNase H-mediated mechanism. This reduces the production of the toxic SOD1 protein. The drug is administered via intrathecal injection through a lumbar puncture at scheduled intervals, under the supervision of trained healthcare professionals. Success in Clinical Trials The approval was supported by data from the phase 3 VALOR study and its open-label extension (OLE). In the VALOR trial, 108 adults with SOD1-ALS were treated with either intrathecal tofersen (n=72) or placebo (n=36) for 28 weeks. The primary endpoint, the ALSFRS-R score — which assesses bulbar, motor, and respiratory functions — showed a positive trend with tofersen, although the difference was not significant. However, tofersen significantly reduced biomarkers of neurodegeneration, including cerebrospinal fluid (CSF) SOD1 protein levels and plasma neurofilament light chain (NfL) concentrations. By week 28, plasma NfL levels decreased by 55% in the tofersen group, compared to a 12% increase with placebo. Clinical trends suggested improvements in respiratory function, muscle strength, and quality of life. These effects were more pronounced with earlier treatment and during the OLE phase. Safety and Tolerability The most common side effects in tofersen-treated patients included: Back, muscle, and joint pain Fatigue Fever Raised CSF protein levels or white blood cell counts These reactions were generally mild to moderate in severity. Further information, including the Patient Information Leaflet and Summary of Product Characteristics, will be available on the MHRA website within 7 days of approval.
Yahoo
an hour ago
- Yahoo
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Key Points The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. 10 stocks we like better than Recursion Pharmaceuticals › Clinical-stage biotech Recursion Pharmaceuticals' (NASDAQ: RXRX) stock took it on the chin in the first trading day of the week. Monday saw investors back out of the company's shares, leaving them with an almost 3% decline at market close. The benchmark S&P 500 (SNPINDEX: ^GSPC) did notably better, ticking up slightly on the day. A rival reports a major step forward This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that targets familial adenomatous polyposis (FAP). This is a rare genetic disease which, when left untreated, typically leads to colorectal cancer. Biodexa has been granted Fast Track status for investigating the drug from the U.S. Food and Drug Administration (FDA). This followed a phase 2 clinical trial in which the drug met its primary endpoints. The advancement of eRapa puts it ahead of Recursion's REC-4881, which is also aimed at treating FAP. The company completed a phase 1b/2 study of the drug earlier this year. Like Biodexa's drug, REC-4881 did well in that stage of testing. The best should win As any seasoned biotech investor would attest, it's the final results and approval process of a drug that ultimately count. Given that, it's hardly encouraging that Biodexa has taken a big step forward ahead of Recursion in the development of its FAP medication. The latter company's investors will be hoping that REC-4881 ultimately proves to be the more efficacious drug for the disorder. Should you invest $1,000 in Recursion Pharmaceuticals right now? Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Recursion Pharmaceuticals Stock Got Mashed on Monday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials
CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidate Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026 CARB-X's additional funding brings their financial support to date for the Alphamer platform and lead compound non-clinical development to $12.3M ALDERLEY PARK, England, July 29, 2025--(BUSINESS WIRE)--Centauri Therapeutics Limited ('Centauri' or 'the Company'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in Centauri's ABX-01 programme into first in human clinical studies, and this latest funding brings CARB-X's total support from 2019 to date to $12.3M. Centauri announced the selection of its first clinical candidate in the ABX-01 programme in March 20251. The candidate is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. Based on the Company's proprietary Alphamer® platform, it is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Early efficacy studies have demonstrated the compound's activity against Gram-negative bacteria. "The unwavering scientific and financial support from CARB-X has provided stability to Centauri as a company, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 programme from discovery, through early development, and is now providing a smooth and continuous path towards First in Human clinical studies," said Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics. "We are thankful for CARB-X and their continued engagement and confidence, which has allowed us to move a step closer to delivering a much needed therapeutic for serious, drug-resistant Gram-negative infections, even in the most clinically vulnerable patients." Dr. Erin Duffy, Chief of Research and Development, CARB-X, commented: "We have been proud to support Centauri, beginning with answering key questions on the approach and continuing with the drug discovery that has led to the lead asset of ABX-01 and its progression towards building a dossier to support its advancement into first in human clinical trials." CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany's Federal Ministry of Research, Technology and Space (BMFTR). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. Press Release (4th March, 2025): Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections View source version on Contacts Media contact Katie OdgaardEmail: Tel: +44 (0) 7787 502 947 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data